Acute Myeloid Leukemia remains a difficult to treat disease. Leukemic stem cells are instrumental for disease pathogenesis. Stemness features also play a crucial role for therapy resistance and relapse. Novel approaches to target leukemic stem cells and to overcome therapy resistance connect basic science and clinicians. In this workshop, we are going to discuss the most recent developments in the translation of basic concepts into clinical applications for and treatment of AML.
Understanding the role of stem-like cells in tumor initiation, progression, and therapy resistance.
Comparing normal developmental processes with oncogenic transformation and tumor heterogeneity.
Novel tools (e.g., organoids, CRISPR, AI) and their use in stem cell and cancer research.
Investigating how epigenetic modifications drive stem cell plasticity and cancer evolution.
The interplay between cancer stem cells, immune evasion, and immunotherapy approaches.
Metabolic reprogramming in stem cells and cancer cells as a therapeutic target.
Harnessing stem cells for tissue repair while avoiding oncogenic risks.
Advances in single-cell genomics, transcriptomics, and proteomics to dissect cellular heterogeneity.
Exploring how the cellular and molecular environment influences stem cell behavior and cancer development.
How cancer stem cells evade treatment and strategies to overcome resistance.
